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Purpose: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in 
the phase 3, double-blind, placebo-controlled PREVAIL trial.
Materials and Methods: Asymptomatic or mildly symptomatic chemotherapy-naïve men with metastatic castration-resistant 
prostate cancer that progressed on androgen deprivation therapy received 160 mg/d oral enzalutamide or placebo (1:1) until 
death or discontinuation due to radiographic progression or skeletal-related event and initiation of subsequent therapy. Coprimary 
end points were centrally assessed radiographic progression-free survival (rPFS) and overall survival (OS). Secondary end points 
included investigator-assessed rPFS, time to initiation of chemotherapy, time to prostate-specific antigen (PSA) progression, PSA 
response (≥50% decline), and time to skeletal-related event.
Results: Of 1,717 total patients, 78 patients were enrolled in Korea (enzalutamide, n=40; placebo, n=38). Hazard ratios (95% con-
fidence interval) for enzalutamide versus placebo were 0.23 (0.02–2.24) for centrally assessed rPFS, 0.77 (0.28–2.15) for OS, 0.21 
(0.08–0.51) for time to chemotherapy, and 0.31 (0.17–0.56) for time to PSA progression. A PSA response was observed in 70.0% 
of enzalutamide-treated and 10.5% of placebo-treated Korean patients. Adverse events of grade ≥3 occurred in 33% of enzalu-
tamide-treated and 11% of placebo-treated Korean patients, with median treatment durations of 13.0 and 5.1 months, respective-
ly. At 13 weeks, the plasma concentration of enzalutamide plus N-desmethyl enzalutamide was similar in Korean and non-Korean 
patients (geometric mean ratio, 1.04; 90% confidence interval, 0.97–1.10).
Conclusions: In Korean patients, treatment effects and safety of enzalutamide were consistent with those observed in the overall 
PREVAIL study population (ClinicalTrials.gov Identifier: NCT01212991).
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INTRODUCTION
In 2012, prostate cancer was the fifth most commonly 
diagnosed malignancy in Korean men, with an estimated 
9,258 new cases detected annually [1]. Nearly 50,000 Korean 
men are living with prostate cancer, of whom 1,460 die from 
the disease each year [1]. Compared with Western countries, 
prostate cancer is less common in Korea (and in Asian 
countries in general) [2], although its prevalence doubled 
between 2002 and 2007, likely due to demographic aging, 
changes in diet, and increased prostate-specific antigen 
(PSA) screening [3-7]. For example, a retrospective analysis 
of  prostate cancer patient data collected between 2006 
and 2010 from a tertiary care center (Gangnam Severance 
Hospital, Yonsei University College of  Medicine, Seoul, 
Korea) revealed a steady increase in the prevalence of 
prostate cancer, with 21% of patients reporting advanced or 
castration-resistant prostate cancer (CRPC) in 2010 [5].
As prostate cancer progresses metastases develop, and 
most cases respond to androgen deprivation therapy (ADT), 
at least initially [8]. Unfortunately, resistance to ADT always 
ensues, resulting in a transition to metastatic CRPC (mCRPC) 
[8-11], a lethal clinical state defined by cancer progression 
despite effective lowering of serum testosterone to <50 ng/
dL or 1.7 nmol/L [12]. Use of docetaxel plus prednisone is 
the current standard of care for mCRPC in Korea [13,14], 
but this regimen is associated with toxicity and, ultimately, 
drug resistance [14,15]. Recent evidence has highlighted the 
ongoing, central role of androgen receptor (AR) signaling in 
CRPC, suggesting that further inhibition of this pathway 
with noncytotoxic therapies may confer a survival benefit. 
Firstly, affected patients often have elevated serum PSA 
levels and measurable intratumoral androgens despite 
castrate levels of  testosterone [16]. Secondly, preclinical 
data showed that AR overexpression is sufficient to confer 
resistance to ADT in prostate cancer cell lines [17,18].
Enzalutamide is an AR inhibitor that has shown 
an 8-fold greater affinity for the AR than bicalutamide 
in studies of  LNCaP/AR cells (half  maximal inhibitory 
concentration, 21 nM vs. 160 nM) [19]. Enzalutamide also 
has the capacity to reduce the efficiency of  AR nuclear 
translocation and impair AR binding to DNA [19]. In 
chemotherapy-naïve men with mCRPC, findings from the 
international, randomized, double-blind, phase 3, PREVAIL 
trial demonstrated that enzalutamide improved overall 
survival (OS; 32.4 months vs. 30.2 months; hazard ratio 
[HR], 0.71; 95% confidence interval [CI], 0.60–0.84; p<0.001) 
and radiographic progression-free survival (rPFS; not yet 
reached vs. 3.9 months; HR, 0.19; 95% CI, 0.15–0.23; p<0.001) [20]. 
PREVAIL data showed that the benefit of enzalutamide 
extended to all secondary end points, including the time 
until the first skeletal-related event (SRE), soft-tissue 
response rate, time until PSA progression, and PSA response 
rate (≥50% decline), as well as patient-reported outcomes [20-
23]. Enzalutamide was approved in Korea in June 2013 for 
use in men with CRPC postchemotherapy based on results of 
the AFFIRM trial. In May 2015 the indication was expanded 
to include men with CRPC regardless of prior chemotherapy 
exposure based on results of the PREVAIL trial [24].
In this post hoc analysis, we evaluated the treatment 
effects, safety, and pharmacokinetic exposure of  enzalu-
tamide versus placebo in PREVAIL patients from Korean 
study sites, as well as the consistency of these results with 
those in the overall population.
MATERIALS AND METHODS
1. Study design and patients
The full methodology of  PREVAIL (NCT01212991), 
including patient eligibility, end point definitions, and study 
conduct has been reported [20]. PREVAIL was approved by 
the independent review board at each participating site and 
was conducted according to provisions of the Declaration 
of Helsinki and Good Clinical Practice Guidelines of the 
International Conference on Harmonization of Technical 
Requirements for Registration of  Pharmaceuticals for 
Human Use.
Brief ly, consenting patients were chemotherapy-
naïve men aged at least 18 years with histologically or 
cytologically confirmed adenocarcinoma of the prostate that 
was castration resistant, with evidence of progression by 
imaging and/or testosterone level of 1.73 nmol/L (50 ng/dL) 
or less. Eligible patients had not received abiraterone acetate, 
had an Eastern Cooperative Oncology Group Performance 
Status (ECOG PS) of  0 (asymptomatic, fully active) or 1 
(ambulatory but restricted in strenuous activities), and were 
asymptomatic or mildly symptomatic based on the Brief 
Pain Inventory Short Form question 3 (i.e., pain score 0–3) [25]. 
Medical castration with a gonadotropin-releasing hormone 
analog was required in patients without orchiectomy. 
Concomitant use of corticosteroids was permitted with doses 
equivalent to 10 mg/d of prednisone or prednisolone. Patients 
with visceral disease or with New York Heart Association 
class I or II heart failure were eligible. Patients with 
conditions that could lower the seizure threshold (e.g., brain 
metastases, history of seizure, concurrent medications), prior 
use of chemotherapy, or New York Heart Association class 
III or IV heart failure were excluded.
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Patients were enrolled from September 2010 through 
September 2012 at 207 sites globally, seven of which were 
in Korea. Korean sites enrolled patients from November 
2011 through September 2012. Patients were randomized 
1:1 to receive either oral enzalutamide 160 mg (Medivation 
Inc., San Francisco, CA, USA and Astellas Pharma 
Inc., Northbrook, IL, USA) or placebo once daily, with 
randomization stratified by study site. Treatment was 
discontinued for occurrence of  unacceptable side effects, 
confirmed radiographic progression, or confirmed SRE and 
either initiation of cytotoxic therapy or an investigational 
agent for prostate cancer.
2. Assessments
The coprimary end points were rPFS determined 
by independent central review and OS. Radiographic 
progression-free survival was defined as the time from 
randomization to the first objective evidence of radiographic 
disease progression assessed by a blinded independent 
central review facility or death due to any cause within 168 
days after treatment discontinuation, whichever occurred 
f irst. Radiographic disease progression was evaluated 
using the Prostate Cancer Clinical Trials Working Group 
[12] guidelines for bone disease and Response Evaluation 
Criteria In Solid Tumors version 1.1 for soft-tissue disease [26] 
and included confirmed new bone lesions and new soft-tissue 
lesions. Imaging was performed at screening, at weeks 9, 17, 
and 25, and every 12 weeks thereafter. Overall survival was 
defined as the time from randomization to death from any 
cause. 
Secondary end points included rPFS by investigator 
review, time to initiation of  chemotherapy, time to PSA 
progression, PSA response, overall soft-tissue response, 
and time to SRE. Time to initiation of chemotherapy was 
defined as the time from randomization to initiation of 
an antineoplastic agent for prostate cancer. Time to PSA 
progression was defined as the time from randomization 
to first confirmed PSA progression. PSA response was 
defined as a decline in PSA of at least 50% from baseline as 
determined by the local laboratory (confirmed by a second 
assessment conducted ≥3 weeks later). Time to SRE was 
defined as the time from randomization to first occurrence 
of radiation therapy or surgery to bone for prostate cancer, 
pathological bone fracture, spinal cord compression, or 
change of antineoplastic therapy to treat bone pain.
Safety was evaluated in all randomized patients who 
received at least one dose of study drug. Adverse events (AEs) 
were graded according to the Common Terminology Criteria 
for Adverse Events version 4. 
In all patients, blood was collected for the determination 
of  predose minimum plasma concentrations (Cmin) of 
enzalutamide and its active metabolite N-desmethyl 
enzalutamide at weeks 5, 13, and 25. The samples were stored 
at –70oC until required for analysis by Covance (Princeton, 
NJ, USA), as described elsewhere. Briefly, both analytes 
were extracted from plasma by a liquid-liquid extraction 
procedure, separated by reversed phase high-performance 
liquid chromatography, and detected by tandem mass 
spectrometry, in accordance with U.S. Food and Drug 
Administration guidance [27]. The quantitation for both 
analytes was 0.02 to 50.0 µg/mL.
3. Statistical analysis
A post hoc  analysis of  patients enrolled in Korean 
study sites at the time of  study entry was performed 
for the coprimary end points, AEs, and all secondary 
and exploratory end points. Final results for the entire 
PREVAIL study were based on 439 centrally assessed rPFS 
events (cutoff  date May 6, 2012) and 540 deaths (cutoff 
date September 16, 2013). Patients randomized after May 6, 
2012, were not included in the final rPFS analysis. Thus, an 
analysis of investigator-assessed rPFS at the final OS data 
cutoff date (September 16, 2013) and an updated exploratory 
analysis of OS at the prespecified final number of deaths 
(≥765; cutoff date June 1, 2014) were also performed.
In this post hoc analysis, baseline characteristics and 
treatment effects were evaluated in the intent-to-treat 
population (all randomly assigned patients). Estimates 
of  medians and 95% CIs were determined using the 
Kaplan-Meier method. The HR relative to placebo, with 
<1.00 favoring enzalutamide, was determined using an 
unstratified Cox regression model with treatment as the 
only covariate. 
The mean minimum concentration of  the sum of 
enzalutamide plus N-desmethyl enzalutamide at weeks 5, 13, 
and 25 were adjusted for weight using log-linear regression. 
The relative systemic exposure to the sum of enzalutamide 
plus N-desmethyl enzalutamide in Korean and non-Korean 
patients was expressed as the ratio of their weight-adjusted 
Cmin values, including 90% CIs. 
RESULTS
1. Patients
The May 6, 2012, cutoff date for the protocol-specified 
interim analysis of centrally assessed rPFS after 439 events 
in the overall PREVAIL population occurred during the 
enrollment period in Korea, thus 38 patients did not have 
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rPFS evaluated by central review (Fig. 1). The investigator-
assessed rPFS and OS results, as well as all other metrics, 
are reported using a data cutoff  of  September 16, 2013, 
determined by the occurrence of 540 protocol-specified deaths 
in the overall study population; at this date all Korean 
patients had enrolled.
Seventy-eight of 1,717 PREVAIL patients were enrolled 
at Korean study sites (enzalutamide, n=40; placebo, n=38). 
Baseline demographic and disease characteristics were well 
balanced between the enzalutamide- and placebo-treated 
Korean patients, except that the proportion of patients with 
an ECOG PS of 0 was lower, and the proportion of patients 
with bone disease or with a prior radical prostatectomy 
was higher in the enzalutamide than placebo group (Table 
1). Compared with the overall study population, Korean 
patients had lower median body weight and body mass 
index, less baseline pain, lower median PSA, less baseline use 
of corticosteroids, greater use of prior antiandrogens, and 
greater use of hormonal therapies, and more had a Gleason 
score of at least 8 at initial diagnosis.
Among Korean patients, median duration of treatment 
was more than twice as long in the enzalutamide as in 
the placebo arm (13.0 months vs. 5.1 months). More Korean 
patients in the enzalutamide group than in the placebo 
group received at least 12 months of treatment (65% vs. 32%) 
and continued to receive treatment as of the September 16, 
2013, data cutoff date (53% vs. 18%).
2. Treatment effects
In the final PREVAIL analysis of  Korean patients, 
enzalutamide was associated with a 77% reduction in 
the risk for centrally assessed radiographic progression 
or death (HR, 0.23; 95% CI, 0.02–2.24; Fig. 2). In Korean 
patients, median rPFS by central assessment was not yet 
reached in the enzalutamide and placebo groups. For rPFS, 
the treatment effect associated with enzalutamide versus 
placebo in Korean patients was similar to that observed in 
the overall study population.
Despite the limited number of  patients available for 
centrally assessed rPFS, a similar relative risk was evident 
when rPFS was investigator assessed (HR, 0.22; 95% CI, 0.11–0.46; 
Fig. 3). Median investigator-assessed rPFS was not yet reached 
in the enzalutamide group (95% CI, 13.6–not yet reached) 
versus 8.0 months in the placebo group (95% CI, 1.9–8.4).
872
871
intervention
Allocated to enzalutamide
- Received allocated intervention
-1 Did not receive allocated
845
844
intervention
Allocated to placebo
- Received allocated intervention
-1 Did not receive allocated
367 Ongoing
504 Discontinued intervention
-17 Death (1.9%)
-355 Disease progression (40.7%)
-49 Adverse event (5.6%)
-21 Patient withdrew consent (2.4%)
-62 Other (7.1%)
61 Ongoing
783 Discontinued intervention
-7 Death (0.8%)
-577 Disease progression (68.3%)
-51 Adverse event (6.0%)
-40 Patient withdrew consent (4.7%)
-108 Other (12.8%)
872 ITT population
871 Safety population
845 ITT population
844 Safety population
40 Korean patients
-21 Ongoing (52.5%)
-19 Discontinued (47.2%)
-12 Disease progression (30.0%)
-2 Adverse event (5.0%)
-5 Other (12.5%)
38 Korean patients
-7 Ongoing (18.4%)
-31 Discontinued (81.6%)
-25 Disease progression (65.8%)
-1 Adverse event (2.6%)
-5 Other (13.2%)
20 Patients enrolled after initial rPFS
analysis (no central review)
18 Patients enrolled after initial rPFS
analysis (no central review)
2,462
Assessed for eligibility
745
Screen failures
1,717
Randomized 1:1*
Fig. 1. PREVAIL patient disposition. ITT, 
intent-to-treat; rPFS, radiographic pro-
gression-free survival. *Randomization 
was stratified by study site.
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Table 1. Patient and disease characteristics at baseline
Parameter
Overall ITT population (n=1,717) Korean patients (n=78)
Enzalutamide 
(n=872)
Placebo  
(n=845)
Enzalutamide 
(n=40)
Placebo  
(n=38)
Age (y) 72.0 (43–93) 71.0 (42–93) 71.0 (56–83) 67.0 (42–85)
Body weight (kg) 83.1 (49–162) 82.8 (34–160) 67.0 (50–78) 70.5 (58–88)
Body mass index (kg/m2) 27.5 (18–47) 27.5 (15–51) 24.4 (19–32) 25.5 (18–30)
Gleason score ≥8 at initial diagnosis (%) 50.6 52.4 81.1 81.6
ECOG PS=0 (%) 67.0 69.2 55.0 76.3
Baseline pain 0–1 on BPI-SF Q3 (%) 66.2 67.5 80.0 84.2
PSA (ng/mL) 54.1 (0–3,182) 44.2 (0–3,637) 25.4 (2–830) 26.2 (0–240)
LDH (IU/L) 185.0 (52–1,816) 185.0 (67–2,321) 191.0 (147–360) 184.5 (135–645)
Baseline use of corticosteroids (%) 4.0 4.3 0 0
Prior antiandrogen use (%) 87.2 86.4 95.0 94.7
≥2 Prior antiandrogen therapies (%) 21.4 20.0 37.5 34.2
≥4 Prior unique hormonal therapies (%) 18.8 17.4 50.0 47.4
History of prior surgery for prostate cancer (%) 51.9 49.3 42.5 26.3
Radical prostatectomya (%) 25.9 26.6 27.5 10.5
Orchiectomya (%) 4.6 5.0 0 2.6
TURPa (%) 14.2 10.4 10.0 10.5
Othera (%) 18.2 17.2 10.0 7.9
Bone disease (%) 85.0 81.7 90.0 78.9
   ≥10 Bone metastases (%) 32.7 32.2 25.0 23.7
Soft-tissue disease (lymph node visceral or other) (%) 59.3 59.6 45.0 42.1
Values are presented as median (range) unless otherwise indicated.
BPI-SF Q3, Brief Pain Inventory Short Form question 3; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ITT, intent-to-treat; 
LDH, lactate dehydrogenase; PSA, prostate-specific androgen; TURP, transurethral resection of the prostate.
a:Patients who had received more than one type of prior surgery for prostate cancer are counted only once in each category.
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Fig. 2. Duration of centrally assessed rPFS in Korean patients and the 
overall study population (data cutoff May 6, 2012). Dashed horizontal 
line indicates median. Hazard ratios are based on unstratified Cox re-
gression models with treatment as the only covariate and values <1.00 
favoring enzalutamide. CI, confidence interval; ENZA, enzalutamide; 
HR, hazard ratio; ITT, intent-to-treat; NYR, not yet reached; PBO, pla-
cebo; rPFS, radiographic progression-free survival.
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Fig. 3. Duration of investigator-assessed rPFS in Korean patients (data 
cutoff September 16, 2013). Dashed horizontal line indicates median. 
Hazard ratios are based on unstratified Cox regression models with 
treatment as the only covariate and values <1.00 favoring enzalu-
tamide. CI, confidence interval; ENZA, enzalutamide; HR, hazard ratio; 
ITT, intent-to-treat; NYR, not yet reached; PBO, placebo; rPFS, radio-
graphic progression-free survival.
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Risk of death was reduced by 23% in Korean patients 
treated with enzalutamide (HR, 0.77; 95% CI, 0.28–2.15) 
relative to those who received placebo (Fig. 4). In the updated 
analysis of OS (June 1, 2014) that included an additional 9 
months of follow-up, the risk of death in Korean patients 
was reduced by 24% (HR, 0.76; 95% CI, 0.34–1.68) with 
enzalutamide relative to placebo (Fig. 5).
With the exception of  median time until first SRE, 
enzalutamide was associated with improved outcomes versus 
placebo in Korean patients for all secondary end points 
(Table 2), as evidenced by longer median times to cytotoxic 
chemotherapy and PSA progression and better PSA response 
rates. 
3. Subsequent antineoplastic and endocrine 
therapies
Among Korean patients, subsequent therapies were 
used by 18% and 66% of enzalutamide- and placebo-treated 
patients, respectively (Table 3). The most common subsequent 
therapies received by Korean patients were docetaxel (13% 
and 58%, respectively) and abiraterone acetate (2.5% and 
10.5%, respectively).
Table 2. Secondary end points in Korean patients and the overall study population at OS data cutoff (September 16, 2013)
End point
Overall ITT population (n=1,717) Korean patients (n=78)
Enzalutamide 
(n=872)
Placebo  
(n=845)
Enzalutamide 
(n=40)
Placebo  
(n=38)
Time until initiation of cytotoxic chemotherapy (mo), median (95% CI) 28.0 (25.8–NYR) 10.8 (9.7–12.2) NYR (NYR–NYR) 11.2 (6.7–NYR)
Hazard ratio (95% CI) 0.35 (0.30–0.40) 0.21 (0.08–0.51)
Time until PSA progression (mo), median (95% CI) 11.2 (11.1–13.7) 2.8 (2.8–2.9) 11.1 (5.7–NYR) 2.9 (2.8–3.8)
Hazard ratio (95% CI) 0.17 (0.15–0.20) 0.31 (0.17–0.56)
Time until first SRE (mo), median (95% CI) 31.1 (29.5–NYR) 31.3 (23.9–NYR) NYR (20.1–NYR) 20.1 (NYR–NYR)
Hazard ratio (95% CI) 0.72 (0.61–0.84) 1.40 (0.46–4.33)
PSA response, ≥50% reduction from baseline, % (95% CI) 78.0 (75.1–80.7) 3.5 (2.3–5.0) 70.0 (53.5–83.4) 10.5 (2.9–24.8)
Best objective soft-tissue responsea (%) 60.0 7.7 61.5 0
OS, overall survival; ITT, intent-to-treat; CI, confidence interval; NYR, not yet reached; PSA, prostate-specific antigen; SRE, skeletal-related event. 
a:Includes complete and partial response, assessed by investigator in patients with measurable disease: Korean patients, enzalutamide (n=13), 
placebo (n=7); overall ITT population, enzalutamide (n=396), placebo (n=381).
Fig. 4. Duration of OS in Korean patients and the overall study popu-
lation (data cutoff Sep 16, 2013). Dashed horizontal line indicates 
median. Hazard ratios are based on unstratified Cox regression models 
with treatment as the only covariate and values <1.00 favoring enzalu-
tamide. CI, confidence interval; ENZA, enzalutamide; HR, hazard ratio; 
ITT, intent-to-treat; NYR, not yet reached; OS, overall survival; PBO, 
placebo.
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4. Safety
The incidence and nature of AEs emergent in Korean 
patients treated with either enzalutamide or placebo were 
comparable to those observed in patients treated with 
enzalutamide or placebo in the overall safety population 
(Table 4). The median treatment durations for the 
Table 3. Subsequent antineoplastic and endocrine therapies
Variable
Overall ITT population (n=1,717) Korean patients (n=78)
Enzalutamide (n=872) Placebo (n=845) Enzalutamide (n=40) Placebo (n=38)
Patients taking ≥1 subsequent therapy 382 (43.8) 642 (76.0) 7 (17.5) 25 (65.8)
Antineoplastic agent 308 (35.3) 515 (60.9) 6 (15.0) 22 (57.9)
Cabazitaxel 51 (5.8) 110 (13.0) 0 (0.0) 3 (7.9)
Cyclophosphamide 7 (0.8) 12 (1.4) 0 (0.0) 2 (5.3)
Docetaxel 286 (32.8) 479 (56.7) 5 (12.5) 22 (57.9)
Estramustine 8 (0.9) 11 (1.3) 1 (2.5) 1 (2.6)
Mitoxantrone 5 (0.6) 9 (1.1) 0 (0) 1 (2.6)
Endocrine therapy 200 (22.9) 438 (51.8) 1 (2.5) 8 (21.1)
Abiraterone acetate 179 (20.5) 385 (45.6) 1 (2.5) 4 (10.5)
Bicalutamide 16 (1.8) 41 (4.9) 0 (0.0) 3 (7.9)
Flutamide 3 (0.3) 7 (0.8) 0 (0.0) 1 (2.6)
Values are presented as number (%).
ITT, intent-to-treat.
Table 4. Summary of treatment-emergent AEs
Parameter
Overall safety population (n=1,715) Korean patients (n=78)
Enzalutamide 
(n=871)
Placebo  
(n=844)
Enzalutamide 
(n=40)
Placebo  
(n=38)
Median duration of treatment (mo) 16.6 4.6 13.0 5.1
   Overview
      Any AE 844 (96.9) 787 (93.2) 37 (92.5) 30 (78.9)
      Any serious AE 279 (32.0) 226 (26.8) 14 (35.0) 3 (7.9)
      Any AE grade ≥3 374 (42.9) 313 (37.1) 13 (32.5) 4 (10.5)
      Drug-related AE grade ≥3 67 (7.7) 54 (6.4) 0 (0) 0 (0)
Any AE listed as primary reason for treatment discontinuation 49 (5.6) 51 (6.0) 2 (5.0) 1 (2.6)
Any AE leading to a dose reduction 18 (2.1) 8 (0.9) 0 (0) 1 (2.6)
Any AE leading to death 37 (4.2) 32 (3.8) 2 (5.0) 0 (0)
Most common AEs (any grade)a
Fatigue 310 (35.6) 218 (25.8) 8 (20.0) 4 (10.5)
Upper respiratory tract infection 53 (6.1) 30 (3.6) 8 (20.0) 3 (7.9)
Back pain 235 (27.0) 187 (22.2) 7 (17.5) 3 (7.9)
Nausea 201 (23.1) 190 (22.5) 6 (15.0) 4 (10.5)
Constipation 193 (22.2) 145 (17.2) 6 (15.0) 2 (5.3)
Flushing 19 (2.2) 3 (0.4) 5 (12.5) 2 (5.3)
Fall 101 (11.6) 45 (5.3) 5 (12.5) 0 (0)
Pollakiuria 50 (5.7) 37 (4.4) 4 (10.0) 4 (10.5)
Dizziness 76 (8.7) 53 (6.3) 4 (10.0) 2 (5.3)
Hematuria 73 (8.4) 49 (5.8) 4 (10.0) 2 (5.3)
Musculoskeletal pain 87 (10.0) 73 (8.6) 4 (10.0) 2 (5.3)
Paresthesia 34 (3.9) 25 (3.0) 4 (10.0) 2 (5.3)
Cataract 20 (2.3) 3 (0.4) 4 (10.0) 0 (0)
Foot fracture 7 (0.8) 1 (0.1) 4 (10.0) 0 (0)
Values are presented as number (%). Results are from the September 16, 2012, data cutoff.
AE, adverse event.
a:Occurring in ≥10% of Korean patients in the enzalutamide group at a higher incidence than in the placebo group.
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enzalutamide and placebo groups were 13.0 and 5.1 months, 
respectively. Among Korean patients, the incidence of 
AEs of grade 3 or greater was higher in the enzalutamide 
group than in the placebo group (33% vs. 11%, respectively), 
although none were considered to be treatment related. The 
most frequent AEs (with >20% incidence) in enzalutamide-
treated Korean patients were fatigue and upper respiratory 
tract infection, most of  which were grade 2 or less. No 
seizures were observed in Korean patients.
5. Pharmacokinetics
The mean Cmin of  the sum of  enzalutamide and 
N-desmethyl enzalutamide in Korean and non-Korean 
patients at 5, 13, and 25 weeks are presented in Table 5. The 
Cmin values of enzalutamide plus N-desmethyl enzalutamide 
at all of these time points were similar in Korean patients 
and non-Korean patients, with geometric mean ratios 
(Korean:non-Korean) of 0.97, 1.04, and 1.03, respectively. 
DISCUSSION
In this post hoc analysis of  asymptomatic or mildly 
symptomatic Korean men with chemotherapy-naïve mCRPC 
who participated in the PREVAIL study, treatment effects 
observed with enzalutamide versus placebo were consistent 
with those observed in the overall study population, 
including centrally assessed rPFS (data cutoff May 6, 2012), 
investigator-assessed rPFS (data cutoff September 16, 2013) 
and a range of secondary end points. 
Some differences in baseline disease characteristics were 
observed in the Korean subgroup relative to the overall 
study population, which were likely related to difference 
in clinical practice. A higher percentage of Korean patients 
had a Gleason score of  at least 8 suggesting a higher 
disease burden, yet they reported less pain and had a lower 
median PSA level at baseline. Compared with the overall 
population of  PREVAIL, a larger proportion of  Korean 
patients received prior antiandrogen therapy, which possibly 
contributed to the lower baseline median PSA level. Unlike 
the overall study population, no Korean patients received 
corticosteroids at baseline.
Aside f rom dif ferences in clinical practice, some 
differences between the baseline characteristics of Korean 
patients and the overall PREVAIL population may be 
related to ethnicity. In men without prostate cancer, 
several studies have shown that Asian men have a lower 
baseline PSA than Caucasians [28,29]. It is uncertain if this 
difference in PSA levels between ethnicities signifies that 
Korean patients have a lower disease burden. Regardless, 
the difference in the proportion of patients with confirmed 
PSA responses (i.e., ≥50% reduction from baseline) between 
the enzalutamide-treated and placebo-treated Korean 
patients was large (70% vs. 11%), suggesting that regular 
PSA monitoring may help physicians evaluate treatment 
response. 
As in the overall study population, Korean patients 
receiving enzalutamide had a more than 2-fold longer 
duration of  therapy than those receiving placebo, and 
incidences of AEs were similar between Korean patients 
and the overall study population. Importantly, there were no 
drug-related AEs of grade 3 or greater in Korean patients 
and no instances of seizure in Korean patients or the overall 
study population. 
As with other post hoc analyses, limitations apply when 
interpreting these results. Notably, PREVAIL was not 
designed to assess differences between enzalutamide and 
placebo in the Korean subgroup given the small number 
of Korean patients included in the study, limited follow-
up duration, and low number of events. These limitations 
lead to median estimates of  OS and rPFS that could be 
considered tentative at the time of analysis and a restriction 
on the ability to detect differences between the AEs of 
enzalutamide- and placebo-treated patients. Acknowledging 
these limitations, we sought to examine the consistency of 
the results in Korean patients with those in the overall 
study population, which was powered sufficiently to detect 
Table 5. Systemic exposure to the sum of enzalutamide plus N-desmethyl enzalutamide (active metabolite) in Korean patients and non-Korean 
patients immediately before dosing at weeks 5, 13, and 25
Time 
point
Enzalutamide plus N-desmethyl enzalutamide Cmin (µg/mL) Ratio of Cmin
Korean patients Non-Korean patients Korean/non-Korean patients
No. Mean (95% CI) Geometric meana No. Mean (95% CI) Geometric meana Geometric meana (90% CI)
Week 5 37 26.2 (24.7–27.7) 21.7 712 22.7 (22.3–23.0) 22.3 0.97 (0.92–1.03)
Week 13 39 28.9 (27.3–30.4) 25.9 704 25.5 (25.1–25.9) 25.0 1.04 (0.97–1.10)
Week 25 34 29.3 (27.4–31.2) 26.0 631 25.9 (25.5–26.3) 25.3 1.03 (0.94–1.13)
Cmin, minimum plasma analyte concentration; CI, confidence interval.
a:Adjusted for weight using log-linear regression.
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the treatment effects and safety of enzalutamide versus 
placebo. 
CONCLUSIONS
In conclusion, this post hoc  analysis of  multicenter, 
randomized, placebo-controlled PREVAIL data confirms 
similar treatment effects and AE profile between Korean 
patients and the overall study population.
CONFLICTS OF INTEREST
Ad Theeuwes is an employee of Astellas. Except for that, 
other authors have nothing to disclose.
ACKNOWLEDGMENTS
PREVAIL was funded by Medivation, Inc., and Astellas 
Pharma, Inc., the codevelopers of  enzalutamide. Medical 
writing and editorial support funded by both sponsor 
companies was provided by Malcolm J. M. Darkes, PhD, 
Nathan Yardley, PhD, and Shannon Davis of  Infusion 
Communications.
REFERENCES
1. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. 
Cancer statistics in Korea: incidence, mortality, survival, and 
prevalence in 2012. Cancer Res Treat 2015;47:127-41.
2. Ferlay J, Soerjomataram I, Erik M, Dikshit R, Eser S, Mathers C, 
et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 11 2013 [Internet]. Lyon 
(FR): International Agency for Research on Cancer; c2016 
[cited 2016 Jan 27]. Available from: http://globocan.iarc.fr.
3. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza 
G. The worldwide epidemiology of prostate cancer: perspec-
tives from autopsy studies. Can J Urol 2008;15:3866-71.
4. Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014;11:197-
212.
5. Lee DH, Jung HB, Chung MS, Lee SH, Chung BH. The change 
of prostate cancer treatment in Korea: 5 year analysis of a 
single institution. Yonsei Med J 2013;54:87-91.
6. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue 
M, et al. Cancer Incidence in Five Continents, Vol. IX. IARC 
Scientific Publications No. 160; 2007 [Internet]. Lyon (FR): In-
ternational Agency for Research on Cancer; c2016 [cited 2016 
Mar 20]. Available from: http://www.iarc.fr/en/publications/
pdfs-online/epi/sp160/.
7. Forman D, Bray F, Brewster D, Gombe Mbalawa C, Kohler B, 
Pineros M, et al. Cancer incidence in five continents, Vol. X. 
IARC Scientific Publications No. 164; 2014 [Internet]. Lyon 
(FR): International Agency for Research on Cancer; c2016 
[cited 2016 Mar 20]. Available from: http://ci5.iarc.fr/Default.
aspx.
8. Kirby M, Hirst C, Crawford ED. Characterising the castration-
resistant prostate cancer population: a systematic review. Int J 
Clin Pract 2011;65:1180-92.
9. Feldman BJ, Feldman D. The development of androgen-inde-
pendent prostate cancer. Nat Rev Cancer 2001;1:34-45.
10. Pienta KJ, Bradley D. Mechanisms underlying the development 
of androgen-independent prostate cancer. Clin Cancer Res 
2006;12:1665-71.
11. Scher HI, Sawyers CL. Biology of progressive, castration-resis-
tant prostate cancer: directed therapies targeting the androgen-
receptor signaling axis. J Clin Oncol 2005;23:8253-61.
12. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Car-
ducci MA, et al. Design and end points of clinical trials for 
patients with progressive prostate cancer and castrate levels of 
testosterone: recommendations of the Prostate Cancer Clinical 
Trials Working Group. J Clin Oncol 2008;26:1148-59.
13. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, 
Tannock IF. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer: updated survival in 
the TAX 327 study. J Clin Oncol 2008;26:242-5.
14. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi 
KN, et al. Docetaxel plus prednisone or mitoxantrone plus 
prednisone for advanced prostate cancer. N Engl J Med 2004; 
351:1502-12.
15. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic 
castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 
8:12-23.
16. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn 
TF, Higano CS, et al. Maintenance of intratumoral androgens 
in metastatic prostate cancer: a mechanism for castration-
resistant tumor growth. Cancer Res 2008;68:4447-54.
17. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, 
et al. Molecular determinants of resistance to antiandrogen 
therapy. Nat Med 2004;10:33-9.
18. Knudsen KE, Scher HI. Starving the addiction: new opportuni-
ties for durable suppression of AR signaling in prostate cancer. 
Clin Cancer Res 2009;15:4792-8.
19. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. 
Development of a second-generation antiandrogen for treat-
ment of advanced prostate cancer. Science 2009;324:787-90.
20. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, 
Higano CS, et al. Enzalutamide in metastatic prostate cancer 
before chemotherapy. N Engl J Med 2014;371:424-33.
21. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, 
183ICUrology 2016;57:174-183. www.icurology.org
PREVAIL Korean post hoc analysis
et al. Increased survival with enzalutamide in prostate cancer 
after chemotherapy. N Engl J Med 2012;367:1187-97.
22. Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, 
et al. Efficacy outcomes by baseline prostate-specific antigen 
quartile in the AFFIRM trial. Eur Urol 2015;67:223-30.
23. Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chow-
dhury S, et al. Effect of enzalutamide on health-related quality 
of life, pain, and skeletal-related events in asymptomatic and 
minimally symptomatic, chemotherapy-naive patients with 
metastatic castration-resistant prostate cancer (PREVAIL): re-
sults from a randomised, phase 3 trial. Lancet Oncol 2015;16: 
509-21.
24. Astellas Pharma Korea Inc. Xtandi [prescribing information]. 
Seoul: Astellas Pharma Korea Inc.; c2016 [updated 2015 May 
22; cited 2016 Mar 20]. Available from: http://www.astellas.
co.kr/product/pdf/xtand_150522.pdf.
25. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief 
Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, 
Rubinstein L, et al. New guidelines to evaluate the response 
to treatment in solid tumors. European Organization for Re-
search and Treatment of Cancer, National Cancer Institute of 
the United States, National Cancer Institute of Canada. J Natl 
Cancer Inst 2000;92:205-16.
27. U.S. Department of Health and Human Services; U.S, Food 
and Drug Administration; Center for Drug Evaluation and Re-
search; Center for Veterinary Medicine. Guidance for industry: 
bioanalytical method validation 2001 [Internet]. Silver Spring 
(MD): U.S. Food and Drug Administration; c2016 [cited 2016 
Jan 30]. Available from: http://www.fda.gov/Drugs/Guidance-
ComplianceRegulatoryInformation/Guidances/UCM070107.
28. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess 
HA, Masumori N, et al. Serum prostate-specific antigen in a 
community-based population of healthy Japanese men: lower 
values than for similarly aged white men. Br J Urol 1995;75: 
347-53.
29. Chia SE, Lau WK, Cheng C, Chin CM, Tan J, Ho SH. Prostate-
specific antigen levels among Chinese, Malays and Indians in 
Singapore from a community-based study. Asian Pac J Cancer 
Prev 2007;8:375-8.
